Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsAvMed Amtagvi (lifileucel) Prior Auth Coverage | O…
    Ask Trek AI about this page
    CurrentAvMedPolicy N/A

    Amtagvi (lifileucel) medical prior authorization

    Customize your policy alerts

    Sign up for all AvMed policy alerts

    Know when AvMed releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization form and medical coverage criteria for Amtagvi (lifileucel) administered under the medical benefit (J9999). Defines patient eligibility, clinical exclusion criteria, dosing limits, provider and site requirements, and documentation/submission instructions for approval of a single lifetime treatment course.

    Policy Summary
    PayerAvMed
    PolicyAmtagvi (lifileucel) medical prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionPrescribing physician must sign and clearly print name on the prior authorization request and fax complete information to 1-877-535-1391; incomplete/illegible submissions may delay authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical/coverage changes

    1Lifetime doses allowed
    18+Minimum member age (years)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=7.5e9Minimum viable cells per dose
    MultipleKey clinical exclusions

    Coverage Summary

    Prior authorization is required for Amtagvi (lifileucel) administered under the medical benefit (HCPCS J9999). The prior authorization form and medical coverage criteria define patient eligibility, clinical exclusion criteria, dosing limits, provider and site requirements, and documentation/submission instructions for approval of a single lifetime treatment course.

    Amtagvi is provided as patient-specific infusion bag(s) with a single-dose, one-time lifetime administration: 1 treatment course (1 dose) per lifetime. The form captures member and prescriber information, clinical eligibility, dosing schedule, and site of administration details necessary for authorization.

    Surface thresholds summary
    Lifetime doses1 treatment course (1 dose) per lifetime
    Minimum member age18 years or older
    Minimum viable cells per doseMinimum of 7.5 x 10^9 viable cells per dose
    LVEF>= 45% (LVEF must NOT be less than 45%)
    NYHA classNYHA functional class <= 1
    FEV1> 60% (FEV1 must NOT be <= 60%)
    Hemorrhage windowNo hemorrhage grade >=2 within 14 days prior to therapy

    Authorization Criteria (All must be met)

    Authorization Criteria (All must be met)

    All criteria must be met for approval. To support each line checked, documentation (lab results, diagnostics, chart notes) must be provided.

    • Lifetime dose: One treatment course (1 dose) per lifetime; coverage may NOT be renewed1 treatment course per lifetime

      Only a single lifetime dose allowed

    • Age: Member is 18 years of age and older>= 18 years

      Must check box and support with documentation

    • Provider specialty:

    Provider Actions & Submission Requirements

    Prior Authorization

    Submit signed prior authorization request

    Prescribing physician must sign and clearly print name on the prior authorization request and fax complete information to 1-877-535-1391. Incomplete, incorrect, or illegible submissions may delay authorization.

    Documentation Required

    Support each criterion with documentation

    All documentation, including laboratory results, diagnostics, and chart notes, must be provided to support each clinical criterion checked on the authorization form. Failure to provide required documentation may result in denial or delay of the request.

    • Lab results
    • Diagnostic reports
    • Chart notes / clinical documentation

    Applicable Codes

    Medical claim HCPCS/Pass-throughHCPCSCovered
    J9999Not otherwise classified drugs (used here for Amtagvi lifileucel)
    Product NDC / package identifierNDCCovered
    73776-0001-xxAmtagvi contains 7.5 x 10^9 to 72 x 10^9 viable cells suspended in 1 to 4 patient-specific infusion bag(s)

    Background

    Amtagvi (lifileucel) is a cell therapy product supplied in patient-specific infusion bag(s) and administered as a single-dose, one-time lifetime therapy. The product is represented on the form as Amtagvi (lifileucel) for medical benefit billing.

    The prior authorization form collects details to document clinical eligibility, dosing and dosing limits (including number of infusion bags and viable cell counts), and the provider/site of administration. The form requires the prescribing physician's signature and provider contact information; incomplete or illegible submissions may delay authorization.

    Treatment course is defined as 1 dose (single administration) of Amtagvi per lifetime.

    Clinical Evidence & Metrics

    All authorization criteria must be met and supported with documentation (lab results, diagnostics, chart notes). Key clinical prerequisites include: patient age of 18 years or older; diagnosis of unresectable or metastatic melanoma (excluding uveal melanoma); administration by an oncologist or a dermatologist with oncology consult/specialty; prior therapy with a PD-1 blocking antibody (and if BRAF V600 mutation-positive, prior BRAF inhibitor with or without a MEK inhibitor); and eligibility for IL-2 (aldesleukin) per the manufacturer's prescribing label.

    Important exclusions and clinical thresholds that must be met prior to treatment include: only a single lifetime dose allowed; no uncontrolled brain metastases; no clinically significant active systemic infection; no hemorrhage grade ≥2 within 14 days prior to therapy; cardiac function thresholds of LVEF not less than 45% and NYHA class ≤ 1; and pulmonary threshold of FEV1 > 60%. Concurrent prophylactic systemic corticosteroids should not be given.

    Clinical thresholds (detailed)
    LVEF>= 45% — Member must NOT have LVEF less than 45%
    NYHA classNYHA functional class <= 1 — Member must NOT be greater than Class 1
    FEV1> 60% — Member must NOT have FEV1 <= 60%

    Revision History

    Policy Summary
    PayerAvMed
    PolicyAmtagvi (lifileucel) medical prior authorization
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionPrescribing physician must sign and clearly print name on the prior authorization request and fax complete information to 1-877-535-1391; incomplete/illegible submissions may delay authorization.
    SourceLink
    On This Page
    Coverage SummaryAuthorization Criteria (All must be met)Provider Actions & Submission RequirementsApplicable CodesBackgroundClinical Evidence & MetricsRevision History
    Provider requesting therapy is an oncologist, or a dermatologist with consult/specialty in oncology
  1. Diagnosis: Member has a diagnosis of unresectable or metastatic melanoma
  2. Uveal melanoma exclusion: Member does NOT have uveal melanoma

    Exclusion

  3. Prior therapies

    • Required prior therapies list: Programmed cell death protein-1 (PD-1) blocking antibody; If BRAF V600 mutation-positive, a BRAF inhibitor with or without a MEK inhibitor
  4. Brain metastases exclusion: Member does NOT have uncontrolled brain metastases

    Exclusion

  5. Renal exclusion: Member does NOT have signs and symptoms of acute renal failure prior to treatment

    Exclusion

  6. Hemorrhage exclusion: Member does NOT have hemorrhage (grade 2 or higher) within 14 days prior to therapyno hemorrhage grade >=2 within 14 days

    Temporal exclusion (14 days)

  7. Cardiac function: Member does NOT have a left ventricular ejection fraction (LVEF) less than 45% or New York Heart Association (NYHA) functional classification greater than Class 1LVEF >= 45%; NYHA class <= 1

    Cardiac function thresholds

  8. Pulmonary function: Member does NOT have forced expiratory volume in one second (FEV1) of less than or equal to 60%FEV1 > 60%

    Pulmonary function threshold

  9. Active infection exclusion: Member does NOT have a clinically significant active systemic infection

    Active infection exclusion

  10. IL-2 eligibility: Member is deemed eligible for IL-2 (aldesleukin) therapy according to the manufacturer's prescribing label

    Eligibility for IL-2 per label required

  11. No prophylactic steroids: Member will NOT receive concomitant prophylactic systemic corticosteroid therapy

    No concomitant prophylactic systemic corticosteroids

  12. Documentation Required

    Provider specialty requirement

    Ensure the requesting provider is an oncologist, or a dermatologist with an oncology consult or oncology specialty documented on the request form.

    Billing Rule

    Dose and dispensing limits

    Dose and dispensing limits: Amtagvi is a single lifetime treatment (one treatment course, one dose per lifetime). Product NDC 73776-0001-xx describes Amtagvi as 7.5 x 10^9 to 72 x 10^9 viable cells suspended in 1 to 4 patient-specific infusion bag(s). Use HCPCS code J9999 for medical benefit billing. Note that the product may be provided in 1–4 patient-specific infusion bags and should be billed on the medical benefit.

    • Single lifetime dose allowed (1 treatment course)
    • Product NDC: 73776-0001-xx
    • HCPCS: J9999
    • Contains 1 to 4 patient-specific infusion bags; bill under medical benefit
    Prior Authorization

    Urgent review process

    For urgent review requests—where lack of treatment could seriously jeopardize life, health, or the member’s ability to regain maximum function—the practitioner should call the AvMed Pre-Authorization Department to request an urgent review.

    Hemorrhage window
    No hemorrhage (grade 2 or higher) within 14 days prior to therapy
    Minimum viable cells per doseSingle dose must contain a minimum of 7.5 x 10^9 viable cells